Nephrology Dialysis Transplantation

Article	Citations
Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA	266
Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey	142
Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls	114
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease	104
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)	88
High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients	83
Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice	81
Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort study	80
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis	79
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)	73
Renal gluconeogenesis: an underestimated role of the kidney in systemic glucose metabolism	72
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial	70
Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease?	69
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)	65
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disea	59
COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study	59
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone	57
Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study	55
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAP	55
Volume overload in hemodialysis: diagnosis, cardiovascular consequences, and management	54
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in a haemodialysis cohort	54
Clinical utility of genetic testing in early-onset kidney disease: seven genes are the main players	48
The impact of chronic kidney disease Stages 3–5 on pregnancy outcomes	47
At least 156 reasons to prioritize COVID-19 vaccination in patients receiving in-centre haemodialysis	44
The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria	44

Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study	42
Performance of creatinine-based equations to estimate glomerular filtration rate in White and Black populations in Europe, Brazil and Africa	39
Prevalence and outcomes of hyponatremia and hypernatremia in patients hospitalized with COVID-19	39
Nephrotic syndrome and vasculitis following SARS-CoV-2 vaccine: true association or circumstantial?	38
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results	37
High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients	36
Urine proteomics for prediction of disease progression in patients with IgA nephropathy	36
Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?	35
Bone evaluation in paediatric chronic kidney disease: clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the	35
Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases	35
What should European nephrology do with the new CKD-EPI equation?	35
How to tackle health literacy problems in chronic kidney disease patients? A systematic review to identify promising intervention targets and strategies	34
Free p-cresyl sulfate shows the highest association with cardiovascular outcome in chronic kidney disease	34
SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, ‘diabetic nephropathy’, IgA nephropathy and podocytopathies with FSGS lesions	33
Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study	33
Management of obesity in kidney transplant candidates and recipients: A clinical practice guideline by the DESCARTES Working Group of ERA	33
Mapping health-related quality of life after kidney transplantation by group comparisons: a systematic review	32
Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2	32
The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant	32
Tissue sodium stores in peritoneal dialysis and hemodialysis patients determined by sodium-23 magnetic resonance imaging	32
Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors	31
Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort	31
Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis	30
Effects of calcitriol and paricalcitol on renal fibrosis in CKD	30
Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease	30
Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment	29
Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion	29
The cholinergic anti-inflammatory pathway in chronic kidney disease—review and vagus nerve stimulation clinical pilot study	28
Removing race from the CKD-EPI equation and its impact on prognosis in a predominantly White European population	28
Chronic kidney disease, physical activity and cognitive function in older adults—results from the National Health and Nutrition Examination Survey (2011–2014)	28
Genetics-first approach improves diagnostics of ESKD patients <50 years old	28
The European Green Deal and nephrology: a call for action by the European Kidney Health Alliance	28
Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years	27
Early versus late acute kidney injury among patients with COVID-19—a multicenter study from Wuhan, China	27
Climate change and nephrology	26
Bleeding risk of haemodialysis and peritoneal dialysis patients	26
The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes	26
Factors associated with sex differences in the risk of kidney stones	26
Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study	26
Renin–angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease	25
Metabolic dysfunction–associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease	25
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis	25
Distal renal tubular acidosis: ERKNet/ESPN clinical practice points	25
Armed conflicts and kidney patients: a consensus statement from the Renal Disaster Relief Task Force of the ERA	25
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS	25
Increasing incidence and improved survival in ANCA-associated vasculitis—a Danish nationwide study	24
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study	24
Assisted peritoneal dialysis and transfer to haemodialysis: a cause-specific analysis with data from the RDPLF	24
Long-term outcomes of COVID-19 survivors with hospital AKI: association with time to recovery from AKI	24
Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis	24

Renal denervation: where do we stand and what is the relevance to the nephrologist?	23
International peritoneal dialysis training practices and the risk of peritonitis	23
Fibrosis and cancer: shared features and mechanisms suggest common targeted therapeutic approaches	23
Effect of hemodiafiltration on measured physical activity: primary results of the HDFIT randomized controlled trial	23
Renal transplant outcomes in amyloidosis	23
SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA	23
Water intake and progression of chronic kidney disease: the CKD-REIN cohort study	22
Causal effects of physical activity or sedentary behaviors on kidney function: an integrated population-scale observational analysis and Mendelian randomization study	22
Patient-reported factors influencing the choice of their kidney replacement treatment modality	22
Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease	22
Interim analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity filter) registry	22
Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia	21
Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults	21
Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment	21
Persistence of antibody response to SARS-CoV-2 in a cohort of haemodialysis patients with COVID-19	21
Tubulointerstitial nephritis and uveitis syndrome: a systematic review	21
Dynapaenia and sarcopaenia in chronic haemodialysis patients: do muscle weakness and atrophy similarly influence poor outcome?	20
Magnesium to prevent kidney disease–associated vascular calcification: crystal clear?	19
Protein carbamylation and chronic kidney disease progression in the Chronic Renal Insufficiency Cohort Study	19
Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study	19
Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis	19
Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study	19
Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis of the SENCOVAC study	18
Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers	18
Lactobacillus rhamnosus L34 attenuates chronic kidney disease progression in a 5/6 nephrectomy mouse model through the excretion of anti-inflammatory molecules	18
Tubular phosphate handling: references from child to adulthood in the era of standardized serum creatinine	18
Heart failure in chronic kidney disease: the emerging role of myocardial fibrosis	18
Does kidney transplantation with a standard or expanded criteria donor improve patient survival? Results from a Belgian cohort	18
COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection	18
Serum hemoglobin concentration and risk of renal function decline in early stages of diabetic kidney disease: a nationwide, biopsy-based cohort study	18
Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE	17
RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease	17
Pre-eclampsia is a valuable opportunity to diagnose chronic kidney disease: a multicentre study	17
Availability of assisted peritoneal dialysis in Europe: call for increased and equal access	17
Peripheral neuropathy: an important contributor to physical limitation and morbidity in stages 3 and 4 chronic kidney disease	17
Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage	17
IgA nephropathy in adults—treatment standard	17
Trends in kidney transplantation rate across Europe: study from the ERA Registry	17
Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease	17
Outcome and effect of vaccination in SARS-CoV-2 Omicron infection in hemodialysis patients: a cohort study	17
Precision medicine approaches for diabetic kidney disease: opportunities and challenges	17
COVID-19 vaccination in haemodialysis patients: good things come in threes…	17
Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials	17
Increasing numbers and improved overall survival of patients on kidney replacement therapy over the last decade in Europe: an ERA Registry study	16
Association of osteopontin with kidney function and kidney failure in chronic kidney disease patients: the GCKD study	16
Immunoglobulin A nephropathy in association with inflammatory bowel diseases: results from a national study and systematic literature review	16
The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification	16
Lessons learned during the war in Ukraine: a report from the Renal Disaster Relief Task Force of the ERA	16
Impact of incremental initiation of haemodialysis on mortality: a systematic review and meta-analysis	16
Sepsis-associated acute kidney injury—treatment standard	16
Efficacy and safety of combination therapy with sodium–glucose cotransporter 2 inhibitors and renin–angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis	16
Long-term renal survival of paediatric patients with lupus nephritis	15
Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis	15
Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis	15
Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of five cases	15
Complement inhibitors for kidney disease	15
C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies	15
Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors	15
Precision medicine in Fabry disease	15
The incidence and prevalence of IgA nephropathy in Europe	15
Results of the European EDITH nephrologist survey on factors influencing treatment modality choice for end-stage kidney disease	15
Systematic review of the nuclear factor erythroid 2-related factor 2 (NRF2) system in human chronic kidney disease: alterations, interventions and relation to morbidity	15
Albuminuria as a risk factor for mild cognitive impairment and dementia—what is the evidence?	15
Can the assessment of ultrasound lung water in haemodialysis patients be simplified?	15
Urinary Dickkopf-3: a new biomarker for CKD progression and mortality	14
Prolonged patient survival after implementation of a continuous quality improvement programme empowered by digital transformation in a large dialysis network	14
Novel in vitro assays to detect circulating permeability factor(s) in idiopathic focal segmental glomerulosclerosis	14
Immune checkpoint inhibitor–associated hypercalcaemia	14
Pre-kidney transplant unintentional weight loss leads to worse post-kidney transplant outcomes	14
The kidney reabsorption-related magnesium depletion score is associated with increased likelihood of abdominal aortic calcification among US adults	14
Tertiary lymphoid tissues: a regional hub for kidney inflammation	14
The risks associated with percutaneous native kidney biopsies: a prospective study	14
Real-time prediction of intradialytic hypotension using machine learning and cloud computing infrastructure	14
Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice	14
Long-term risks after kidney donation: how do we inform potential donors? A survey from DESCARTES and EKITA transplantation working groups	14
Identification of a serum and urine extracellular vesicle signature predicting renal outcome after kidney transplant	14
Dietary magnesium supplementation inhibits abdominal vascular calcification in an experimental animal model of chronic kidney disease	14
Clinical events and patient-reported outcome measures during CKD progression: findings from the Chronic Renal Insufficiency Cohort Study	14
Mechanisms of myostatin and activin A accumulation in chronic kidney disease	14
DNA methylation profiling identifies epigenetic differences between early versus late stages of diabetic chronic kidney disease	14

CONVINCE in the context of existing evidence on haemodiafiltration	14
Humoral response after SARS-CoV-2 vaccination in patients undergoing maintenance haemodialysis: loss of immunity, third dose and non-responders	14
Survival of patients who opt for dialysis versus conservative care: a systematic review and meta-analysis	14
Effect of fructooligosaccharide on endothelial function in CKD patients: a randomized controlled trial	14
Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study	13
Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy	13
Renal denervation in patients with chronic kidney disease: current evidence and future perspectives	13
Adding creatinine to routine pregnancy tests: a decision tree for calculating the cost of identifying patients with CKD in pregnancy	13
Overcoming barriers in the design and implementation of clinical trials for acute kidney injury: a report from the 2020 Kidney Disease Clinical Trialists meeting	13
Pilot study of reloxaliase in patients with severe enteric hyperoxaluria and hyperoxalemia	13
Factors influencing fertility rates in Australian women receiving kidney replacement therapy: analysis of linked Australia and New Zealand Dialysis and Transplant Registry and perinatal data over 22 y	13
The influence of repeated flares in response to therapy and prognosis in lupus nephritis	13
Inflammation and physical dysfunction: responses to moderate intensity exercise in chronic kidney disease	13
Itching in dialysis patients: impact on health-related quality of life and interactions with sleep problems and psychological symptoms—results from the RENINE/PROMs registry	13
Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s	13
Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in haemodialysis patients: a multicentre study	13
An intradialytic non-immersive virtual reality exercise programme: a crossover randomized controlled trial	13
Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease	13
Sex difference in ambulatory blood pressure control associates with risk of ESKD and death in CKD patients receiving stable nephrology care	13
Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis	13
Perspectives on mental health among patients receiving dialysis	13
Patient-reported outcome measures for life participation in peritoneal dialysis: a systematic review	12
Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects	12
Effect of anti-angiotensin II type 1 receptor antibodies on the outcomes of kidney transplantation: a systematic review and meta-analysis	12
Semiquantitative assessed proteinuria and risk of heart failure: analysis of a nationwide epidemiological database	12
Barriers to conservative care from patients’ and nephrologists’ perspectives: the CKD-REIN study	12
Diffusion kurtosis imaging as an imaging biomarker for predicting prognosis in chronic kidney disease patients	12
Using a generic definition of cachexia in patients with kidney disease receiving haemodialysis: a longitudinal (pilot) study	12
Screening of Fabry disease in patients with chronic kidney disease in Japan	12
Cardiopulmonary exercise testing in patients with end-stage kidney disease: principles, methodology and clinical applications of the optimal tool for exercise tolerance evaluation	12
Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last two decades	12
Evaluation of severity of delayed graft function in kidney transplant recipients	12
The basics of phosphate metabolism	12
Long-term impact of cardiorenal syndromes on major outcomes based on their chronology: a comprehensive French nationwide cohort study	12
Cytomegalovirus after kidney transplantation in 2020: moving towards personalized prevention	12
Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies	12
Intravenous sodium thiosulphate for vascular calcification of hemodialysis patients—a systematic review and meta-analysis	12
Assessment of a modified renal angina index for AKI prediction in critically ill adults	12
mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?	12
Association of renal impairment with cognitive dysfunction in the Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA)	12
Association of single and serial measures of serum phosphorus with adverse outcomes in patients on peritoneal dialysis: results from the international PDOPPS	12
Comparison of the association between six different frailty scales and clinical events in patients on hemodialysis	11
Combining phosphate binder therapy with vitamin K2 inhibits vascular calcification in an experimental animal model of kidney failure	11
Work status and work ability of patients receiving kidney replacement therapy: results from a European survey	11
Plasma exchange in ANCA-associated vasculitis: the pro position	11
Impact of different COVID-19 waves on kidney replacement therapy epidemiology and mortality: REMER 2020	11
Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial	11
Dialysis withdrawal in The Netherlands between 2000 and 2019: time trends, risk factors and centre variation	11
Validity and reliability of the Patient-Reported Outcomes Measurement Information System (PROMIS®) using computerized adaptive testing in patients with advanced chronic kidney disease	11
High rates of psychological distress, mental health diagnoses and suicide attempts in people with chronic kidney disease in Ireland	11
Temporal trends in the quality of deceased donor kidneys and kidney transplant outcomes in Europe: an analysis by the ERA-EDTA Registry	11
Serum levels of IL-6, IL-8 and IL-10 and risks of end-stage kidney disease and mortality	11
Urea levels and cardiovascular disease in patients with chronic kidney disease	11
Patterns of renal osteodystrophy 1 year after kidney transplantation	11
Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges	11
Haemodiafiltration for all: are we CONVINCEd?	11
Home-based exercise in patients on maintenance dialysis: a systematic review and meta-analysis of randomized clinical trials	11
Asystole episodes and bradycardia in patients with end-stage renal disease	11
Definition, diagnosis and clinical management of non-obstructive kidney dysplasia: a consensus statement by the ERKNet Working Group on Kidney Malformations	11
Neutrophil:lymphocyte ratio correlates with the uremic toxin indoxyl sulfate and predicts the risk of death in patients on hemodialysis	11
Effects of the chymase inhibitor fulacimstat in diabetic kidney disease—results from the CADA DIA trial	11
The role of complement in glomerulonephritis—are novel therapies ready for prime time?	11
COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab	11
Long-term effectiveness of a primary care practice facilitation program for chronic kidney disease management: an extended follow-up of a cluster-randomized FROM-J study	11
Nesfatin-1 treatment preserves antioxidant status and attenuates renal fibrosis in rats with unilateral ureteral obstruction	11
Association of tubular solute clearances with the glomerular filtration rate and complications of chronic kidney disease: the Chronic Renal Insufficiency Cohort study	11
Increased risk of ischaemic heart disease after kidney donation	11
Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells	11
Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in haemodialysis patients	11
Management of antineutrophil cytoplasmic antibody–associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations	11
Recommended calcium intake in adults and children with chronic kidney disease—a European consensus statement	10
The level of urinary C4d is associated with disease progression in IgA nephropathy with glomerular crescentic lesions: a cohort study	10
#3848 ORIGIN TRIAL: 24-WK PRIMARY ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PH2B STUDY OF ATACICEPT IN PATIENTS WITH IGAN	10
High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database	10
SARS-CoV-2 vaccination in patients receiving kidney replacement therapies: where are we now with the protective immune response?	10
Impact of dialysis modality on major adverse cardiovascular events and all-cause mortality: a national population-based study	10
Association of serum globulin with all-cause mortality in incident hemodialysis patients	10
Availability, coverage, and scope of health information systems for kidney care across world countries and regions	10
Hypertension in chronic kidney disease—treatment standard 2023	10
Circulating angiopoietin-2 and angiogenic microRNAs associate with cerebral small vessel disease and cognitive decline in older patients reaching end-stage renal disease	10
Surgical versus endovascular intervention for vascular access thrombosis: a nationwide observational cohort study	10
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial	10
LIMS1 risk genotype and T cell–mediated rejection in kidney transplant recipients	10
Serum bicarbonate is associated with kidney outcomes in autosomal dominant polycystic kidney disease	10
Country-specific sex disparities in living kidney donation	10
Comorbidities and outcomes in South Asian individuals with chronic kidney disease: an observational primary care cohort	10
Remnant cholesterol is prospectively associated with cardiovascular disease events and all-cause mortality in kidney transplant recipients: the FAVORIT study	10
Determining the optimal cholecalciferol dosing regimen in children with CKD: a randomized controlled trial	10
Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib	10
Cardiovascular calcifications in kidney transplant recipients	10
Subsequent urinary stone events are predicted by the magnitude of urinary oxalate excretion in enteric hyperoxaluria	10
Association of blood pressure with cardiovascular outcome and mortality: results from the KNOW-CKD study	10
Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation	10
Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association	10
Electronic alerts and a care bundle for acute kidney injury—an Australian cohort study	10